SCHEMBL4384599

SCHEMBL4384599

Cc1ccc(NC(=O)N2CCC(=Cc3cccc(OCC4CCCCO4)c3)CC2)cn1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.58
CYP2D6 P10635 4/20 0.58
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
LMNA P02545 1/20 0.42
GRM5 P41594 2/20 0.41
POLB P06746 1/20 0.41
FAAH O00519 2/20 0.41
GABRA1 P14867 1/20 0.41
ADRA2C P18825 1/20 0.41
CNR1 P21554 1/20 0.41
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
CNR2 P34972 1/20 0.41
HTR2B P41595 1/20 0.41
TMEM97 Q5BJF2 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1039557 0.91 CYP3A4 (0.53) CYP3A4CYP2D6NPC1RAB9ASMN1; SMN2
SCHEMBL1037574 0.90 CYP3A4 (0.57) CYP3A4CYP2D6SMN1; SMN2FAAHGABRA1
SCHEMBL1036158 0.89 CYP3A4 (0.63) CYP3A4CYP2D6FAAHGABRA1ADRA2C
SCHEMBL1038006 0.85 SMN1; SMN2 (0.42) CYP3A4CYP2D6NPC1RAB9ASMN1; SMN2
SCHEMBL1040115 0.84 FAAH (0.56) CYP3A4CYP2D6NPC1RAB9ASMN1; SMN2
SCHEMBL1040265 0.83 CYP3A4 (0.47) CYP3A4CYP2D6NPC1RAB9ALMNA
SCHEMBL1036113 0.83 FAAH (0.58) CYP3A4CYP2D6NPC1RAB9ASMN1; SMN2
SCHEMBL6526889 0.82 CYP3A4 (0.39) CYP3A4CYP2D6NPC1RAB9ASMN1; SMN2
SCHEMBL1039403 0.82 CYP3A4 (0.65) CYP3A4CYP2D6FAAHGABRA1ADRA2C
SCHEMBL1075998 0.82 CYP3A4 (0.59) CYP3A4CYP2D6FAAHGABRA1ADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009127944-A1 ETHER BENZYLIDENE PIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS PFIZER INC. (US) 2009-10-22 WO disclosed
US-7538241-B2 Hsp90 family protein inhibitors KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-05-26 US disclosed
US-20070155813-A1 Hsp90 family protein inhibitors KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-07-05 US disclosed
EP-1704856-A1 HSP90 FAMILY PROTEIN INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-09-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155813-A1 Hsp90 family protein inhibitors HSP90AB1, HEATR1, HSP90AB2P CYP3A4 1704/4885CYP2D6 1749/4885NPC1 1090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.